Introduction {#S0001}
============

Lung cancer remains the most commonly diagnosed cancer and the leading cause of cancer-related deaths, with 2.1 million new cases and 1.8 million deaths in 2018 worldwide.[@CIT0001],[@CIT0002] Of all pathological types, non-small cell lung cancer (NSCLC) accounts for approximate 85% of all lung cancers and more than 65% of the patients with NSCLC present with locally advanced or metastatic disease.[@CIT0003],[@CIT0004]

The major treatment options for patients with NSCLC are determined on the basis of histologic features and staging according to the eighth edition of the TNM (T, N, and M represent tumor, lymph node, and metastasis, respectively) classification for lung cancer.[@CIT0005] Generally, the current treatment for lung cancer patients who have been diagnosed at an early stage is surgical resection followed by chemotherapy; however, majority of the patients will eventually experience disease progression and require further treatment.[@CIT0006],[@CIT0007] Paclitaxel, either as single agent or combined with other therapeutics, has shown significant anti-NSCLC activity.[@CIT0008]--[@CIT0010] In advanced stages of NSCLC, the efficacy of paclitaxel in combination with a platinum compound has also been confirmed by a meta-analysis of 16 randomized trials.[@CIT0011] However, either intrinsic or acquired resistance to paclitaxel frequently occurs and represents a significant clinical problem.[@CIT0012] We had previously shown that microRNA-mediated epigenetic targeting of survivin significantly enhances the antitumor activity of paclitaxel against NSCLC.[@CIT0013] In the current report, we investigated both the gene and miRNAs expression profiles in paclitaxel-resistant large-cell lung carcinoma cells, a pathological type of relative small population of NSCLC. An integrative analysis of miRNAs and gene expression profiles was also carried out.

Materials and methods {#S0002}
=====================

Reagents and antibodies {#S0002-S2001}
-----------------------

Paclitaxel was obtained from the 900th Hospital of the Joint Logistics Team pharmacy (the Former Fuzhou General Hospital). The CellTiter96 AQ cell proliferation kit (Cat.\#G3582) was a product of Promega (Madison, WI, USA). Oligonucleotides were synthesized in Sangon (Shanghai, China). Antibodies against PARP (Cat.\#9542) and Caspase-3 (Cat.\#9665) were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA); antibody against β-actin (Cat.\#A5441) was the product of Sigma (St. Louis, MO, USA).

Cells and cell culture {#S0002-S2002}
----------------------

Human large-cell lung carcinoma cell line H460 was obtained from American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS). All cells were cultured in a 37ºC humidified atmosphere containing 95% air and 5% CO~2~ and were split twice a week.

To mimic the development of acquired paclitaxel resistance in vitro, parental H460 cells were maintained in culture medium with low dose of paclitaxel started from 1 nmol/L initially. Cells were then split twice a week and maintained in culture medium with gradually increased dose of paclitaxel every 2 weeks. After 6 months, paclitaxel-resistance NSCLC cells developed from H460 were maintained in culture medium with 40 nmol/L of paclitaxel for normal culture.

Cell viability assay {#S0002-S2003}
--------------------

The CellTiter96 AQ cell proliferation kit (Cat.\#G3582, Promega) was used to determine cell viability as previously described.[@CIT0013] Briefly, cells were plated onto 96-well plates for 24 hrs, and then grown in either RPMI1640 medium with 0.5% FBS as control or the same medium containing different concentrations of paclitaxel, and then incubated for another 72 hrs. During this period, the medium was refreshed daily maintaining the same treatment. After reading all wells at 490 nm with a microplate reader, the percentages of surviving cells from each group relative to controls, defined as 100% survival, were determined by reduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS).

Clonogenic assay {#S0002-S2004}
----------------

The parental and paclitaxel-resistant human SCLC cancer cells H460 were plated onto 6-well plates and incubated at 37°C with 5% CO~2~. After 24 hrs, the culture medium was replaced daily with 2 mL fresh medium containing 0.5% FBS or the same medium containing indicated concentrations of paclitaxel for long-term incubation. After 2 weeks, cells were stained with 0.5% crystal violet (dissolved in 25% methanol) and clone number was quantified with QuantiOne software of Fluor-S^TM^ Multimager (Bio-Rad Laboratories, Inc., Hercules, CA) at the end of the experiments.

Western blotting analysis and quantification of apoptosis {#S0002-S2005}
---------------------------------------------------------

Protein expression and activation were determined by Western blotting analysis as previously described.[@CIT0014] In brief, equal amounts of cell lysates in a buffer (containing 50 mmol/L Tris (pH 7.4), 50 mmol/L NaCl, 0.5% NP40, 50 mmol/L NaF, 1 mmol/L Na~3~VO~4~, 1 mmol/L phenylmethylsulfonyl fluoride, 25 μg/mL leupeptin, and 25 μg/mL aprotinin) were boiled in sodium dodecyl sulfate (SDS) sample buffer (0.0625 mol/L Tris (pH 6.8), 2% SDS, 10% Glycerol, 5% 2-mercaptoethanol, 0.002% Bromophenol-B), resolved by SDS-polyacrylamide gel electrophoresis and Western blotted with specific antibodies directed against PARP (1:1000), Caspase-3 (1:1000), or β-actin (1:10000), as described in the figure legends. For quantification of apoptosis, an apoptosis enzyme-linked immunosorbent assay kit (Cat.\#11774425001, Roche Diagnostics Corp., Indianapolis, IN, USA) was used to quantitatively measure cytoplasmic histone-associated DNA fragments (mononucleosomes and oligonucleosomes) as previously reported.[@CIT0014]

Microarray analysis of both mRNA and miRNA followed by integrative analysis {#S0002-S2006}
---------------------------------------------------------------------------

Total RNAs were prepared from parental and paclitaxel-resistant H460 cells (H460_Parental and H460_TaxR, respectively) with miRNeasy Mini Kit (QIAGEN, GmBH, Germany). For mRNA and miRNA profiling, Agilent G3 Human (8\*60 K) Chip and Agilent Human miRNA Chip (8\*60 K) V19.0 (Agilent technologies, Santa Clara, CA, USA) were used, respectively. Microarray analysis was performed in triplicate in Shanghai Biochip Co., Ltd (Shanghai, China). Either mRNA or miRNA with two-fold change and a *P*\<0.05 between parental and paclitaxel-resistant H460 cells was taken as significantly differentially expressed. The mRNA and miRNA expression profiles were then subjected to integrative analysis in Shanghai Center for Bioinformation Technology (Shanghai, China).

Analysis of differentially expressed mRNAs and miRNAs with real-time quantitative reverse transcriptase PCR (qRT-PCR) {#S0002-S2007}
---------------------------------------------------------------------------------------------------------------------

Total RNA was prepared using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA). First-strand cDNA was generated using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA) following the manufacturer's instructions. To quantify the mRNA level of *MAPT* (forward primer: 5ʹ-AAGATCGGCTCCACTGAGAA-3; reverse primer: 5ʹ-ATGAGCCACACTTGGAGGTC-3ʹ), qRT-PCR was performed using the FastStart Universal SYBR Green Master Mixes (Roche) by a 7900HT Fast Real-Time PCR system (Applied Biosystems) as we had described previously.[@CIT0015] The expression of β-actin was used as an internal control (forward primer: 5ʹ-AGAGCTACGAGCTGCCTGAC-3; reverse primer: 5ʹ-AGCACTGTGTTGGCGTACAG-3ʹ). The expression of mature miR-362-3p, miR-766-3p, miR-6507-3p, and RNU6B was measured by qRT-PCR using TaqMan Assays (Applied Biosystems) as described previously.[@CIT0015] The relative mRNA and miRNA levels were calculated using the comparative Ct method (2^−ΔΔCt^).

Statistical analysis {#S0002-S2008}
--------------------

All results were confirmed by at least three independent experiments. Data are presented as mean±SD. Student's *t*-test or one-way ANOVA was carried out to analyze the differences between two groups or multiple groups. Values of *P*\<0.05 were considered significant.

Results {#S0003}
=======

Establishment of paclitaxel-resistant NSCLC cells {#S0003-S2001}
-------------------------------------------------

To establish a stable NSCLC cell subline with significant resistance to paclitaxel, parental H460 cells were subjected to growth in culture medium with gradually increased dose of paclitaxel persistently to mimic the development of acquired drug resistance in vitro. Six months later, NSCLC cell subline with significant resistance to paclitaxel was developed from parental H460 without obvious morphology change (data not shown). The subline was nominated as H460_TaxR. As shown in [Figure 1A](#F0001){ref-type="fig"}, the IC~50~ values of paclitaxel were 4.824 nmol/L and 41.209 nmol/L for parental and paclitaxel-resistant H460 cells, respectively. The IC~50~ value for paclitaxel-resistant H460 cells increased 8.542-fold as compared with that of parental H460 cells. The significant resistance to anti-proliferative/anti-survival effects of paclitaxel in H460_TaxR cells was further confirmed by clonogenic assay ([Figure 1B](#F0001){ref-type="fig"} and [C](#F0001){ref-type="fig"}). Moreover, results from both Western blotting analysis and quantification of apoptosis showed that while treatment with as low as a dose of 1.5 nmol/L of paclitaxel induced significant apoptosis in parental H460 cells; however, for H460_TaxR cells, even treatment with 12 nmol/L of paclitaxel could only induce a few apoptosis ([Figure 1D](#F0001){ref-type="fig"} and [E](#F0001){ref-type="fig"}). Collectively, our results demonstrated that an NSCLC cell subline H460_TaxR with significant resistance to paclitaxel was established successfully.Figure 1Identification of paclitaxel-resistant NSCLC cells.**Notes:** (**A**) Human NSCLC cells (H460_Parental and H460_TaxR) treated with indicated concentrations of paclitaxel for 72 h were subjected to cell viability assay. (**B, C**) H460_Parental and H460_TaxR cells were grown in triplicates in the absence or presence of indicated concentrations of paclitaxel for 2--3 weeks. The pictures and numbers of the cell colonies were obtained by the QuantiOne software of Fluor-S^TM^ Multimager. (**D, E**) H460_Parental and H460_TaxR cells were treated with indicated concentrations of paclitaxel for 24 hrs. Cells were collected and subjected to Western blot analyses of PARP, Casp-3 or β-actin (**D**), or apoptotic-ELISA (**E**).**Abbreviations:** F-PARP, full length of poly(ADP-ribose) polymerase; C-PARP, cleaved PARP; Pro-Casp-3, Caspase-3; C-Casp-3, cleaved caspase-3; ELISA, enzyme-linked immunosorbent assay.

Gene expression profile in paclitaxel-resistant NSCLC cells {#S0003-S2002}
-----------------------------------------------------------

Next, to gain a more comprehensive knowledge of the underlying molecular mechanism of paclitaxel-resistance in NSCLC, microarray analysis was carried out to investigate the gene expression profile in H460_TaxR cells with significant resistance to paclitaxel. The expression of 652 genes was found to be changed at least 2-fold in H460_TaxR cells with 511 upregulated and 141 downregulated as compared with parental H460 cells ([Figure 2](#F0002){ref-type="fig"}, *P*\<0.05). Of these genes, the top 10 genes that were most significantly up- or downregulated in H460_TaxR cells are shown in [Table 1](#T0001){ref-type="table"}. Gene Ontology (GO, <http://www.geneontology.org>) function enrichment analysis based on our own microarray data showed that the differentially expressed genes in H460_TaxR cells mainly involved in regulating the cell proliferation, cell death, and response to endogenous stimulus. ([Table 2](#T0002){ref-type="table"}). Meanwhile, Gene Set Enrichment Analysis (GSEA) revealed that those differentially expressed genes were clustered in pathways such as cancer,[@CIT0016] signaling by GPCR, cytokine and cytokine receptor interaction, and so on ([Table 3](#T0003){ref-type="table"}).Table 1Representative differentially expressed genes in paclitaxel-resistant NSCLC cellsGene symbolGene nameGenbank accession no.Fold change*P*-values**Top ten upregulated genes in H460_TaxR as compared with H460_Parental***TIMP3*TIMP metallopeptidase inhibitor 3NM_00036284.398276284.48E-05*LINGO2*Leucine rich repeat and Ig domain containing 2NM_15257046.800884710.002291*MYRIP*Myosin VIIA and Rab interacting proteinNM_01546034.750027070.01062*GPR65*G protein-coupled receptor 65NM_00360829.055552430.008347*MARCKS*Myristoylated alanine-rich protein kinase C substrateNM_00235628.251077740.00012*ASTN1*Astrotactin 1NM_20710827.449820070.004438*ANXA3*Annexin A3NM_00513927.282518610.014142*ABCB1*ATP-binding cassette, sub-family B (MDR/TAP), member 1NM_00092724.972923430.001563*WNT4*\
*INSM1*Wingless-type MMTV integration site family, member 4\
insulinoma-associated 1NM_030761\
NM_00219624.6898816\
23.843039870.001894\
0.002524**Top ten downregulated genes in H460_TaxR as compared with H460_Parental***SLFN11*Schlafen family member 11NM_0011045870.0595338550.026053*NTS*NeurotensinNM_0061830.0671254780.001581*PAEP*Progestagen-associated endometrial proteinNM_0025710.067379480.005147*DRD2*Dopamine receptor D2NM_0007950.0696129410.002336*KIAA1324L*KIAA1324-likeNM_1527480.0709888160.004444*LOC100507127*Uncharacterized LOC100507127NR_0382910.0893650660.004397*CHRNA9*Cholinergic receptor, nicotinic, alpha 9NM_0175810.1066673350.005473*GABBR2*Gamma-aminobutyric acid (GABA) B receptor, 2NM_0054580.1111751390.018236*PTX3*Pentraxin 3, longNM_0028520.1146267880.006955*BAIAP2L2*BAI1-associated protein 2-like 2NM_0250450.139308310.000128 Table 2Function enrichment analysis of differentially expressed genes in paclitaxel-resistant NSCLC cellsGene set nameGenes in overlap*P*-valueFDR q-valueGO_REGULATION_OF_CELL_PROLIFERATION786.10E-303.75E-26GO_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT803.16E-289.70E-25GO_TISSUE_DEVELOPMENT752.53E-275.18E-24GO_RESPONSE_TO_LIPID561.45E-252.23E-22GO_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND691.98E-252.43E-22GO_REGULATION_OF_CELL_DIFFERENTIATION716.39E-256.54E-22GO_RESPONSE_TO_ORGANIC_CYCLIC_COMPOUND554.45E-243.91E-21GO_REGULATION_OF_CELL_DEATH697.39E-245.67E-21GO_RESPONSE_TO_ENDOGENOUS_STIMULUS681.58E-231.08E-20GO_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS602.88E-231.77E-20GO_POSITIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS664.69E-232.62E-20GO_REGULATION_OF_CELLULAR_COMPONENT_MOVEMENT491.30E-226.65E-20GO_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION492.09E-219.87E-19GO_RESPONSE_TO_EXTERNAL_STIMULUS732.82E-211.24E-18GO_REGULATION_OF_HYDROLASE_ACTIVITY619.90E-214.05E-18GO_RESPONSE_TO_HORMONE501.10E-204.23E-18GO_EPITHELIUM_DEVELOPMENT512.17E-207.39E-18GO_NEUROGENESIS623.19E-209.78E-18GO_RESPONSE_TO_STEROID_HORMONE371.37E-194.00E-17GO_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION551.69E-194.73E-17GO_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION681.29E-183.44E-16GO_POSITIVE_REGULATION_OF_CELL_DEVELOPMENT351.53E-183.92E-16GO_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT432.65E-186.50E-16GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS704.10E-189.69E-16GO_REGULATION_OF_ANATOMICAL_STRUCTURE_MORPHOGENESIS491.47E-173.35E-15GO_NEGATIVE_REGULATION_OF_CELL_PROLIFERATION391.60E-173.51E-15GO_REGULATION_OF_CELL_DEVELOPMENT442.52E-175.33E-15GO_EMBRYO_DEVELOPMENT455.68E-171.16E-14GO_POSITIVE_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT326.71E-171.33E-14GO_REGULATION_OF_CELLULAR_LOCALIZATION546.98E-171.34E-14GO_NEGATIVE_REGULATION_OF_CELL_COMMUNICATION527.61E-171.42E-14GO_RESPONSE_TO_ABIOTIC_STIMULUS488.02E-171.45E-14GO_CELLULAR_RESPONSE_TO_ORGANIC_SUBSTANCE669.02E-171.58E-14GO_BIOLOGICAL_ADHESION481.08E-161.80E-14GO_CELL_DEVELOPMENT571.09E-161.80E-14GO_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS611.26E-162.04E-14GO_NEGATIVE_REGULATION_OF_RESPONSE_TO_STIMULUS552.38E-163.75E-14GO_POSITIVE_REGULATION_OF_CELL_PROLIFERATION422.76E-164.20E-14GO_MOVEMENT_OF_CELL_OR_SUBCELLULAR_COMPONENT532.80E-164.20E-14GO_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY584.23E-166.18E-14GO_POSITIVE_REGULATION_OF_HYDROLASE_ACTIVITY444.49E-166.36E-14GO_LOCOMOTION494.56E-166.36E-14GO_POSITIVE_REGULATION_OF_CELL_COMMUNICATION586.32E-168.44E-14GO_CARDIOVASCULAR_SYSTEM_DEVELOPMENT402.49E-153.19E-13GO_CIRCULATORY_SYSTEM_DEVELOPMENT402.49E-153.19E-13GO_CELL_MOTILITY413.38E-154.15E-13GO_LOCALIZATION_OF_CELL413.38E-154.15E-13 Table 3Clustered pathways analysis of differentially expressed genes in paclitaxel-resistant NSCLC cellsGene set nameGenes in overlap*P*-valueFDR q-valueKEGG_PATHWAYS_IN_CANCER172.13E-071.18E-04REACTOME_SIGNALING_BY_GPCR302.19E-071.18E-04KEGG_LYSOSOME101.11E-064.00E-04REACTOME_HEMOSTASIS191.59E-064.28E-04REACTOME_GPCR_LIGAND_BINDING174.20E-067.82E-04REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION124.36E-067.82E-04REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL88.38E-061.29E-03KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION131.11E-051.49E-03REACTOME_GPCR_DOWNSTREAM_SIGNALING241.57E-051.88E-03REACTOME_GPVI_MEDIATED_ACTIVATION_CASCADE52.23E-052.40E-03REACTOME_METABOLISM_OF_LIPIDS_AND_LIPOPROTEINS173.21E-052.99E-03KEGG_BASAL_CELL_CARCINOMA63.35E-052.99E-03REACTOME_SIGNALLING_BY_NGF113.60E-052.99E-03REACTOME_COLLAGEN_FORMATION64.55E-053.28E-03REACTOME_DEVELOPMENTAL_BIOLOGY154.57E-053.28E-03BIOCARTA_ALK_PATHWAY55.42E-053.47E-03REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION75.47E-053.47E-03REACTOME_IMMUNE_SYSTEM255.98E-053.58E-03REACTOME_G\_ALPHA_I\_SIGNALLING_EVENTS107.35E-054.17E-03BIOCARTA_CYTOKINE_PATHWAY49.43E-054.85E-03KEGG_FOCAL_ADHESION109.45E-054.85E-03KEGG_AXON_GUIDANCE81.04E-045.04E-03KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION61.12E-045.04E-03KEGG_COMPLEMENT_AND_COAGULATION_CASCADES61.22E-045.04E-03KEGG_P53_SIGNALING_PATHWAY61.22E-045.04E-03KEGG_PPAR_SIGNALING_PATHWAY61.22E-045.04E-03REACTOME_KERATAN_SULFATE_BIOSYNTHESIS41.86E-047.42E-03REACTOME_SIGNALING_BY_ILS72.02E-047.77E-03REACTOME_BILE_ACID_AND_BILE_SALT_METABOLISM42.16E-048.04E-03KEGG_MAPK_SIGNALING_PATHWAY112.26E-048.11E-03REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM112.49E-048.38E-03REACTOME_GLYCOSAMINOGLYCAN_METABOLISM72.53E-048.38E-03REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS62.57E-048.38E-03REACTOME_SIGNALING_BY_RHO_GTPASES72.83E-048.86E-03BIOCARTA_INFLAM_PATHWAY42.88E-048.86E-03KEGG_CHEMOKINE_SIGNALING_PATHWAY93.02E-049.02E-03REACTOME_KERATAN_SULFATE_KERATIN_METABOLISM43.29E-049.58E-03KEGG_HEDGEHOG_SIGNALING_PATHWAY53.99E-041.13E-02KEGG_ERBB_SIGNALING_PATHWAY64.33E-041.20E-02BIOCARTA_CLASSIC_PATHWAY34.54E-041.22E-02REACTOME_GASTRIN_CREB_SIGNALLING_PATHWAY_VIA_PKC_AND_MAPK95.24E-041.32E-02REACTOME_ION_TRANSPORT_BY_P\_TYPE_ATPASES45.38E-041.32E-02KEGG_NEUROTROPHIN_SIGNALING_PATHWAY75.46E-041.32E-02REACTOME_AXON_GUIDANCE105.59E-041.32E-02BIOCARTA_ERYTH_PATHWAY35.63E-041.32E-02BIOCARTA_NUCLEARRS_PATHWAY35.63E-041.32E-02REACTOME_CLASS_A1_RHODOPSIN_LIKE_RECEPTORS116.90E-041.58E-02 Figure 2mRNA expression profiles in parental and paclitaxel-resistant NSCLC cells.**Note:** The heatmap from unsupervised hierarchical clustering showed mRNAs with high expression in red and mRNAs with low expression in green.

MiRNAs expression profile in paclitaxel-resistant NSCLC cells {#S0003-S2003}
-------------------------------------------------------------

MiRNA has emerged as an important regulator in chemoresistance.[@CIT0017] Thus, microarray analysis was also carried out to investigate the miRNAs expression profile in H460_TaxR cells with significant resistance to paclitaxel in our study. As shown in [Figure 3](#F0003){ref-type="fig"} and [Table 4](#T0004){ref-type="table"}, the expression of 43 miRNAs was found to be changed at least 2-fold in H460_TaxR cells with 15 upregulated and 28 downregulated as compared with parental H460 cells (*P*\<0.05). A total of 289 pairs of miRNA-potential target gene were revealed in paclitaxel-resistant NSCLC cells by bioinformatics analysis.Table 4Differentially expressed miRNAs in paclitaxel-resistant NSCLC cellsSystematic nameActive_sequencemirbase Accession NoFold changeStandard deviation (SD)*P*-values**Upregulated miRNAs in H460_TaxR as compared with H460_Parental***hsa-miR-501-5p*TCTCACCCAGGGACAAAGMIMAT000287230.434031.3355918660.02809*hsa-miR-630*ACCTTCCCTGGTACAGAMIMAT000329928.52870.3649710210.0346*hsa-miR-564*GCCTGCTGACACCGTMIMAT000322827.436580.653220480.015002*hsa-miR-718*CGACGCCCGGCMIMAT001273511.464381.0744243320.044477*hsa-miR-4745-5p*CGCCGTCCCGGMIMAT00198783.0283840.5045247390.025545*hsa-miR-2392*CACCTCTCACCCCCMIMAT00190432.8283470.4081715540.01474*hsa-miR-642a-3p*GGTTCCCTCTCCAAATMIMAT00209242.4716850.4879461920.037868*hsa-miR-1181*CGGCTCGGGTGGMIMAT00058262.4478570.1267436280.000237*hsa-miR-3663-3p*GCGCCCGGCCTMIMAT00180852.3718320.3913593740.017977*hsa-miR-937-5p*CCAGCCCCACCCMIMAT00229382.3236160.2935765680.006291*hsa-miR-371a-5p*AGTGCCCCCACAGMIMAT00046872.316230.0392618380.009611*hsa-miR-4327*CCAGTCCCCCATGCMIMAT00168892.0766010.2761856520.011899*hsa-miR-4281*CCCCCCTCCCCGMIMAT00169072.0646590.1476287030.001511*hsa-miR-4271*CCCCACCTTTTCTTCCMIMAT00169012.0235210.1118649330.000326*hsa-miR-1290*TCCCTGATCCAAAAATCCMIMAT00058802.0027670.403830080.048135**Downregulated miRNAs in H460_TaxR as compared with H460_Parental***hsa-miR-1260a*TGGTGGCAGAGGTGGMIMAT00059110.4688330.2276837650.003831*hsa-miR-1260b*ATGGTGGCAGTGGTGMIMAT00150410.4371840.2675837970.008619*hsa-miR-6165*CTCCCCTCACCTCCMIMAT00247820.4196380.0945142230.000272*hsa-miR-590-5p*CTGCACTTTTATGAATAAGCTCMIMAT00032580.4092670.46100210.036474*hsa-miR-106b-5p*ATCTGCACTGTCAGCACMIMAT00006800.4022970.5321304030.046242*hsa-miR-6085*TGTGCTCCCCCAGCMIMAT00237100.3977640.1249206830.002828*hsa-miR-5100*AGAGGCACCGCTGGMIMAT00222590.3868850.3600477050.010945*hsa-miR-4286*GGTACCAGGAGTGGGMIMAT00169160.3356450.3698934810.007076*hsa-miR-19a-3p*TCAGTTTTGCATAGATTTGCAMIMAT00000730.3307370.4058042040.018967*hsa-miR-16-2-3p*TAAAGCAGCACAGTAATATTGGMIMAT00045180.1618670.8042180510.015342*hsa-miR-634*GTCCAAAGTTGGGGTGCTMIMAT00033040.1611480.7641240370.014464*hsa-miR-629-5p*AGTTCTCCCAACGTAAACMIMAT00048100.1451860.9361377410.015935*hsa-miR-193a-3p*ACTGGGACTTTGTAGGCMIMAT00004590.1050370.8828160380.020123*hsa-miR-362-3p*TGAATCCTTGAATAGGTGTGMIMAT00046830.0970670.8771971550.018939*hsa-miR-3180-5p*CGACGTGGGGCGMIMAT00150570.0938960.8724937510.013877*hsa-miR-223-3p*TGGGGTATTTGACAAACTGACMIMAT00002800.0823921.5340402760.02651*hsa-miR-4436b-5p*GGCAGGGCAGGCMIMAT00199400.0675770.8120831640.00396*hsa-miR-129-2-3p*ATGCTTTTTGGGGTAAGGGMIMAT00046050.0654780.8492987930.003717*hsa-miR-301a-3p*GCTTTGACAATACTATTGCACMIMAT00006880.0623411.2980150490.028585*hsa-miR-4310*GGGACATGAATGCTGCMIMAT00168620.0537971.2943327790.012988*hsa-miR-6507-3p*GGGAAAAATAGGAAGGACMIMAT00254710.048231.0465987160.020597*hsa-miR-1539*GGGCATCTGGGACGMIMAT00074010.044431.2561470460.018077*hsa-miR-101-3p*TTCAGTTATCACAGTACTGTMIMAT00000990.044160.9967989940.007266*hsa-miR-766-3p*GCTGAGGCTGTGGGGCTMIMAT00038880.0397390.9283031170.008182*hsa-miR-98-3p*GGGAAAGTAGTAAGTTGTAMIMAT00228420.0391221.1768272770.013799*hsa-miR-487b*AAGTGGATGACCCTGTACMIMAT00031800.0339050.3784648440.002894*hsa-miR-4252*TGGTGCTGACTCAGTGMIMAT00168860.0173710.5066917080.000647 Figure 3miRNA expression profiles in parental and paclitaxel-resistant NSCLC cells.**Note:** The heatmap from unsupervised hierarchical clustering showed miRNAs with high expression in red and miRNAs with low expression in green.

Integrative analysis of miRNAs and gene expression profiles revealed that dysregulated MAPT-targeting microRNAs confer paclitaxel resistance in NSCLC {#S0003-S2004}
-----------------------------------------------------------------------------------------------------------------------------------------------------

Cumulative studies had indicated that microtubule-associated protein tau (MAPT) play an important role in mediating the sensitivity of paclitaxel in several types of tumor including breast cancer.[@CIT0018],[@CIT0019] Since our current gene expression profiling also showed that the *MAPT* mRNA was significantly upregulated in H460_TaxR cells as compared with parental H460 (Fold-change=6.31, *P*=3.46E-03; [Figure 4A](#F0004){ref-type="fig"}), we then focused our integrative analysis on candidate miRNAs targeting *MAPT* mRNA. Of all 28 downregulated miRNAs in H460_TaxR cells, 3 of them including miR-362-3p, miR-766-3p, and miR-6507-3p whose expression was verified by qRT-PCR were predicted to target *MAPT* mRNA via searching in miRDB (<http://www.mirdb.org>) with at least one binding site in its 3ʹ-UTR ([Figure 4B](#F0004){ref-type="fig"} and [C](#F0004){ref-type="fig"}). Meanwhile, miR-362-3p and miR-766-3p were also predicted to target *MAPT* mRNA by TargetScan (<http://www.targetscan.org>). Furthermore, a MAPT-subnetwork was constructed via searching in STRING database (<http://string-db.org>) in combination with analysis of potential targets of miR-362-3p, miR-766-3p, and miR-6507-3p. As shown in [Figure 4D](#F0004){ref-type="fig"}, 13 of 14 potential targets of miR-362-3p, miR-766-3p, and miR-6507-3p were upregulated in H460_TaxR cells ([Table 5](#T0005){ref-type="table"}) and could form a MAPT-subnetwork with protein--protein interactions. Taken together, our integrative analysis of miRNAs and gene expression profiles revealed that dysregulated a couple of microRNAs might confer paclitaxel resistance in NSCLC especially large-cell lung carcinoma via targeting MAPT simultaneously.Table 5Differentially expressed genes in MAPT-subnetwork in paclitaxel-resistant NSCLC cellsGene symbolGene nameGenbank accessionFold change*P*-values**Upregulated genes in H460_TaxR as compared with H460_Parental**MAPTMicrotubule-associated protein tauNM_0168356.3158433050.007459131AKT3V-akt murine thymoma viral oncogene homolog 3NM_1816904.5301195290.007494871GUCY1A2Vuanylate cyclase 1, soluble, alpha 2NM_00085510.449501170.000226547JUNJun proto-oncogeneNM_0022284.4645718760.000278815COL1A1Collagen, type I, alpha 1NM_0000884.1292724020.019058353WIPI2WD repeat domain, phosphoinositide interacting 2NM_0156102.9350718190.027975988ENSAEndosulfine alphaNM_2071682.081122350.019189465SEMA4FSema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4FNM_0042632.5545509980.038460426OPN3Opsin 3NM_0143222.1675896810.002040084NANOS1Nanos homolog 1NM_1994612.0216031950.02355948APBA2Amyloid beta (A4) precursor protein-binding, family A, member 2NM_0055032.3373052190.010474828POFUT1Protein O-fucosyltransferase 1NM_1722362.387532140.018840513ADAMTSL1ADAMTS-like 1NM_0010402726.1000668110.011256879**Downregulated gene in H460_TaxR as compared with H460_Parental**SYT12Synaptotagmin XIINM_1779630.2161139650.038129845 Figure 4MAPT-subnetwork in paclitaxel-resistant NSCLC cells.**Notes:** (**A**) qRT-PCR analysis of mRNA level of *MAPT* in H460_Parental and H460_TaxR. (**B**) qRT-PCR analysis of miRNAs levels of miR-766-3p, miR-362-3p, and miR-6507-3p in H460_Parental and H460_TaxR. **(C**) Diagram of targeting sequences of miR-766-3p, miR-362-3p, and miR-6507-3p in 3ʹ-UTR of *MAPT* mRNA. (**D**) Diagram of constructed MAPT-subnetwork in paclitaxel-resistant non-small cell lung cancer cells. Green, downregulated; Red, upregulated.**Abbreviations:** MAPT, microtubule-associated protein tau; qRT-PCR, quantitative reverse transcriptase PCR; 3ʹ-UTR, 3ʹ-untranslated region.

Discussion {#S0004}
==========

Paclitaxel, initially derived from the bark of the Pacific yew tree, has long been used to treat NSCLC either as single-agent or combined with other therapeutics.[@CIT0008],[@CIT0009],[@CIT0019] Treatment with paclitaxel disables spindle division and causes cell cycle arrest in phase G1/G2 of mitosis as well as induces apoptosis.[@CIT0020] However, resistance to paclitaxel remains one of the main causes of treatment failure in NSCLC.[@CIT0012] It is of particular significance to elucidate the underlying mechanism of paclitaxel resistance and identify new strategy to abrogate it.

Mechanisms of the resistance to paclitaxel are complex as indicated by cumulative studies, which include alterations in microtubule dynamics, altered expression of β-tubulin isotypes, and also deregulated signaling pathways.[@CIT0021]--[@CIT0024] In our own serial studies, we have demonstrated that activation of PI-3K/Akt signaling plays a critical role in ErbB2/ErbB3-mediated therapeutic resistance to paclitaxel mainly via upregulation of survivin.[@CIT0014],[@CIT0025] In addition, we have also found that microRNA-mediated epigenetic targeting of survivin significantly enhances the antitumor activity of paclitaxel against NSCLC.[@CIT0012] Unexpectedly, as we did not observe the change of survivin in our established paclitaxel-resistant NSCLC cells (data not shown), an integrative gene expression profiling was applied to explore the possible novel underlying molecular mechanism of paclitaxel-resistance in NSCLC in our current study. We showed that a total of 43 miRNAs and 652 protein-encoding genes, functionally enriched in regulating the fundamental biological processes including cell proliferation and clustered in pathways such as cancer, are differentially expressed in paclitaxel-resistant NSCLC cells, which suggest that the mechanism of resistance to paclitaxel is more complicated than we had ever recognized.

Upon binding to a pocket in beta-tubulin, paclitaxel inhibits the microtubule depolymerization process and interferes the progression of normal cell cycle.[@CIT0019] MAPT, being a microtubule-associated protein which promotes the assembly of tubulin into microtubules to stabilize microtubule structure,[@CIT0026] has been shown to compete with paclitaxel via sharing the same site.[@CIT0027] As anticipated, a large body of studies had indicated that MAPT plays an important role in mediating the sensitivity of paclitaxel in several types of tumor.[@CIT0018],[@CIT0019],[@CIT0028]--[@CIT0030] Consistently, we also found that the mRNA expression of MAPT was significantly upregulated in paclitaxel-resistant NSCLC cells. However, the underlying mechanism of deregulated expression of MAPT remains largely unknown currently. A study by Wu and colleagues showed that miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel via regulating MAPT.[@CIT0031] Recently, miR-186 was also showed to regulate paclitaxel sensitivity of NSCLC via targeting MAPT.[@CIT0032] Interestingly, although both aforementioned two miRNAs remain unchanged in our established paclitaxel-resistant NSCLC cells, our integrative analysis of miRNAs and gene expression profiles revealed that deregulated miR-362-3p, miR-766-3p, and miR-6507-3p and their 13 potential targets could form a MAPT-subnetwork with protein--protein interactions and confer paclitaxel resistance in NSCLC ([Figure 4D](#F0004){ref-type="fig"}). Currently, since the molecular mechanism underlying deregulated miR-362-3p, miR-766-3p, and miR-6507-3p remains largely unclear, it would be of great interest to unveil it. Besides, whether there exists a causal relationship between specific silence of triple microRNAs (miR-362-3p, miR-766-3p, and miR-6507-3p) and upregulation of MAPT awaits further investigation. Taken together, our findings shed new light on the mechanism of paclitaxel resistance in NSCLC especially large-cell lung carcinoma and suggested that specific manipulation of MAPT-targeting miRNAs may be a novel strategy to overcome paclitaxel resistance in patients with NSCLC in the future.
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NSCLC, non-small cell lung cancer; MAPT, microtubule-associated protein tau; qRT-PCR, quantitative reverse transcriptase PCR; 3ʹ-UTR, 3ʹ-untranslated region; PARP, poly (ADP-ribose) polymerase; C-PARP, cleaved PARP; C-Casp-3, cleaved Caspase-3; ELISA, enzyme-linked immunosorbent assay.
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